3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDIV
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
3
Tumor-Agnostic
1
Thoracic
1
Genitourinary
1
Breast
1
Conditions
Carcinoma, Renal Cell
62
Prostatic Neoplasms
35
Kidney Neoplasms
18
Carcinoma, Transitional Cell
17
Melanoma
15
Urinary Bladder Neoplasms
14
Neoplasm Metastasis
12
Carcinoma, Non-Small-Cell Lung
12
Clear-cell metastatic renal cell carcinoma
11
Colorectal Neoplasms
9
Neoplasms
8
Carcinoma, Hepatocellular
8
Squamous Cell Carcinoma of Head and Neck
7
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
6
Lung Neoplasms
6
Uterine Cervical Neoplasms
5
Stomach Neoplasms
5
Pancreatic Neoplasms
5
Urogenital Neoplasms
4
Small Cell Lung Carcinoma
4
Endometrial Neoplasms
4
Carcinoma, Merkel Cell
4
Urethral Neoplasms
3
Penile Neoplasms
3
Neuroblastoma
3
Liver Neoplasms
3
Brain Neoplasms
3
Wilms Tumor
2
Ureteral Neoplasms
2
Interventions
pembrolizumab
6
Radiosurgery
5
Docetaxel
5
enzalutamide
4
darolutamide
3
Radiotherapy
3
Everolimus
3
Androgen Antagonists
3
relugolix
2
luprolide acetate gel depot
2
Surveys and Questionnaires
2
Standard of Care
2
Radiotherapy, Image-Guided
2
Radiofrequency Ablation
2
Panobinostat
2
Leuprolide
2
Abiraterone Acetate
2
trastuzumab deruxtecan
1
talazoparib
1
spartalizumab
1
siremadlin
1
sipuleucel-T
1
sargramostim
1
resiquimod
1
polysaccharide-K
1
poly ICLC
1
palbociclib
1
olaparib
1
liposomal doxorubicin
1
ixabepilone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Ipilimumab
×
Genitourinary
×
Clear all
NCT03695835
2020-07-22
NIRPA
Gary Onik MD
Completed
27 enrolled